CellMaxLife launches US study of blood test for colorectal cancer: 4 key insights

Cancer diagnostics company CellMaxLife launched Zenith, the U.S. trial of its circulating tumor cell blood test to detect colorectal cancer.

Here are four things to know:

1. Patients coming in for routine colorectal cancer screening through colonoscopy or stool tests will be offered CellMaxLife's blood test, and the results will be compared to the colonoscopy and stool test results.

2. CellMaxLife is partnering with medical centers such as Stanford (Calif.) Medicine, the U.S. Department of Veterans Affairs Palo Alto (Calif.) Health Care System, Baltimore-based Johns Hopkins and the University of Southern California in Los Angeles for the study.

3. A previous trial in Asia found that the test can detect colorectal cancer at an early stage with between 84 and 88 percent accuracy, according to results presented at the 2018 ASCO Gastrointestinal Cancer Symposium in January.

4. CellMaxLife will pursue reimbursement for the test by submitting it through the Parallel Review Program for FDA approval and CMS coverage determination. The test requires one tube of blood and is at a price point of less than $200.

More articles on gastroenterology:

GI leader to know: Dr. Henry Fisher of Digestive Health Consultants

4 things to know about Kansas City VA Medical Center's new head of endoscopy Dr. Ahmed Saeed

Lumendi receives FDA 510(k) clearance for new interventional scissors: 4 things to know

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast